TABLE 3.

Comparison of the effects of SSG formulations on the parasite burdens of different L. donovani strains^a

Strain and treatment	% Suppression (mean ± SE)
	Spleen	Liver	Bone marrow
20001b
SSG	25 ± 10	97 ± 2**	86 ± 5**
PBS-NIV	50 ± 0*	7 ± 7	51 ± 11*
SSG-NIV	63 ± 22	94 ± 4**	95 ± 5**
20003b
SSG	13 ± 10	21 ± 18	24 ± 14
PBS-NIV	ND	ND	ND
SSG-NIV	33 ± 24	95 ± 1***	24 ± 14
20006
SSG	41 ± 12*	97 ± 0.9***	46 ± 15
PBS-NIV	0.3 ± 0.3	8 ± 6	15 ± 9
SSG-NIV	99 ± 0.9***	99.6 ± 0.2***	98 ± 0.8***
20009
SSG	52 ± 13**	98 ± 0.5***	43 ± 17
PBS-NIV	27 ± 17	9 ± 9	2 ± 2
SSG-NIV	98 ± 1***	99.8 ± 0.1***	97 ± 1***
200011
SSG	24 ± 17	18 ± 6	19 ± 15
PBS-NIV	15 ± 7	0.25 ± 0.25	7 ± 7
SSG-NIV	17 ± 10	92 ± 1***	47 ± 12***
200015
SSG	11 ± 11	18 ± 6	10 ± 10
PBS-NIV	6 ± 6	7 ± 2	9 ± 5
SSG-NIV	84 ± 14***	98 ± 0.5***	79 ± 13*
200016
SSG	36 ± 19	99 ± 0.25	52 ± 28
PBS-NIV	41 ± 17	29 ± 3	1 ± 1
SSG-NIV	88 ± 4**	99.7 ± 0.01***	77 ± 14**
MHOM/ET/67:LV82
SSG	29 ± 12	98 ± 1***	20 ± 20
PBS-NIV	14 ± 4	13 ± 9	42 ± 4
SSG-NIV	99 ± 1***	99.6 ± 0.15***	99 ± 0.8***

^aBALB/c mice were infected with different strains of L. donovani amastigotes and treated on day 7 postinfection with PBS (controls) (data not shown), SSG [300 mg of Sb(V)/kg], SSG-NIV [300 mg of Sb(V)/kg], or PBS-NIV (NIV control). On day 14 postinfection, parasite burdens in the liver, spleen, and bone marrow were determined. The mean reduction in parasite burdens was calculated relative to the mean control burdens for the relevant site. In comparison to the value for the relevant controls, the values in some cases were significantly different at a P of <0.001 (***), <0.01 (**), and <0.05 (*). ND, not determined. 

^bTreated as described in footnote a, except animals were treated on day 8 postinfection and were sacrificed on day 15 postinfection.